JSKN003 has shown a 63% objective response rate and 7.7 months median progression-free survival in PROC patients, with higher efficacy in HER2-positive subgroups. The FDA's fast track designation ...

Fast Company’s 11th annual Innovation Festival takes over New York City this September 15–18. Though every year introduces new offerings to the Innovation Festival, we’re also bringing back an ...

ABBV-CLS-628 is currently being evaluated in a phase 2 trial in an estimated 240 adults with ADPKD class 1C, 1D, or 1E. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ADX-2191 is an intravitreal formulation of methotrexate.

A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...

Please provide your email address to receive an email when new articles are posted on . The fast track designation will expedite the review process for urcosimod. Urcosimod had positive results in a ...